La terapia electroconvulsiva en el síndrome neuroléptico maligno / Electroconvulsive therapy in neuroleptic malignant syndrome

Resumen: Uno de los efectos adversos más importantes de los neurolépticos es la posibilidad de desencadenar el síndrome neuroléptico maligno (NMS). El diagnóstico se determina por exclusión y el manejo terapéutico inicial será retirado por neurolépticos por la administración de benzodiacepinas y, en casos extremos, el uso de la terapia electroconvulsiva (ECT). La ECT es una opción terapéutica eficaz en estos pacientes y en esos casos se obtiene una mala respuesta a la administración con fármacos antipsicóticos. Basándonos en el caso del artículo «Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant síndrome. A case report¼ donde se describe el manejo exitoso del uso de relajantes no despolarizantes y su reversor específico en terapias electroconvulsivas en pacientes diagnosticados de síndrome neuroléptico maligno, comentamos la fisiopatología e implicaciones anestésicas además de similitudes con otras entidades hipertérmicas, como es la hipertermia maligna.

Abstract: One of the most important adverse effects of neuroleptics is the possibility of triggering neuroleptic malignant syndrome (NMS). The diagnosis is determined by exclusion and the initial therapeutic management will be withdrawn by neuroleptics by the administration of benzodiazepines and, in extreme cases, the use of electroconvulsive therapy (ECT). ECT is an effective therapeutic option in these patients and in these cases a poor response to administration with antipsychotic drugs is obtained. Based on the case of the article «Rocuronium-sugammadex for the management of electroconvulsive therapy in neuroleptic malignant syndrome. A case report¼ where the successful management of the use of non-depolarizing relaxants and their specific reversal in electroconvulsive therapies in patients diagnosed with of malignant neuroleptic syndrome, we comment on the pathophysiology and anesthetic images as well as similarities with other hyperthermic entities, such as malignant hyperthermia.

A Comparative Study Between Rocuronium And Succinylcholine In Evaluating Endotracheal Intubating Conditions In Day Care Surgeries

Background: Succinylcholine has been the main neuromuscular blocking agent for the endotracheal intubation in rapid sequence induction with some adverse effects. This study was conducted to find a better alternate drug with minimal adverse effects and easy for intubations. Thus, our study aimed to compare the onset time, duration of action, intubating condition and hemodynamic effect of rocuronium bromide at the dose of 0.8 mg/kg and Succinylcholine at the dose of 1.5 mg/kg. Materials and methods: A double blinded randomized control study was conducted among 60 patients undergoing surgery each groups having 30 patients, Duration of action, Hemodynamic parameters, and intubating conditions were assessed after administering drugs in each group. Appropriate statistical tests were applied P value < 0.05 was considered to be significant Results: The mean of onset of action of succinylcholine is significantly shorter than that of rocuronium (48.07 ± 4.04 Vs 74.4 ± 9.1); and duration of action succinylcholine is significantly shorter than that of the rocuronium (3.85 ± 0.33 Vs 44.4 ± 4.7). Both the drugs significantly elevated mean Heart rate, Systolic Blood Pressure, Diastolic Blood pressure, MAP from intubation to subsequent intervals. Conclusion: The rocuronium bromide (0.8 mg/kg) has longer duration of action and slower onset of action than succinylcholine (1.5 mg/kg) with excellent intubating condition and minimal alteration in hemodynamic profile. Hence rocuronium bromide (0.8 mg/kg) can be used as an alternative to Succinylcholine (1.5 mg/kg) in selected situations.

Analysis of metabolites of rocuronium bromide in human bile and the study of transmembrane transport mechanism / 药学学报

Rocuronium bromide is an acetylcholine N2 receptor antagonist, which can be used as an auxiliary drug for general anesthesia. It has been reported that rocuronium has two possible metabolic pathways: N-dealkylation and O-deacetylation, which are mainly taken up by liver and excreted by bile in the form of primary drugs. In this paper, the metabolites of rocuronium in human bile were detected by UHPLC-QE-orbitrap-MS, thirteen metabolites were detected, including eleven phase I metabolites and two phase II metabolites, eleven of which had not been previously reported. At the same time, HEK293 cells overexpressing transporter were used to explore the transmembrane transport mechanism of rocuronium, the results showed that rocuronium was the substrate of MATE1, OCT1, OATP1B1 and OATP1B3. The above research results enrich the metabolic pathway of rocuronium in vivo, and put forward the possible transport mechanism of liver uptake and bile excretion, which can better guide the accurate and safe clinical drug application. The collection of human bile samples in this study was approved by the ethics committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (Approval Number: 2019-775-130-01).

Effects of rocuronium, sugammadex and rocuronium-sugammadex complex on coagulation in rats / Efeitos do rocurônio, sugamadex e complexo rocurônio-sugamadex sobre a coagulação em ratos

Abstract Background and objectives: Sugammadex is an alternative pharmacological drug capable of reversing neuromuscular blockades without the limitations that are presented by anticholinesterase drugs. Coagulation disorders that are related to treatment with sugammadex were reported. The exact mechanism of the effects on coagulation are not fully understood. The objective of this research is to evaluate the effects of rocuronium, sugammadex and the rocuronium-sugammadex complex on coagulation in an experimental model in rats. Methods: This is an experimental randomized animal study. Wistar rats were randomly assigned into the following groups: the Control Group; the Ssal Group - 0.5 mL of intravenous saline; the Sugammadex Group - intravenous sugammadex (100 mg kg−1); and the Rocuronium-Sugammadex Group - intravenous solution with rocuronium (3.75 mg kg−1) and sugammadex (100 mg kg−1). Anesthesia was performed by using isoflurane with controlled ventilation. Coagulation factors were measured 10 minutes after the end of the preoperative preparation and 30 minutes after the administration of the drugs in accordance with the chosen groups. Results: Platelet counts, prothrombin times, and activated partial thromboplastin times were similar between the groups and between the moments within each group. There were reductions in the plasma fibrinogen levels between sample times 1 and 2 in the Rocuronium-Sugammadex group (p = 0.035). Conclusions: The rocuronium-sugammadex complex promoted reductions in plasma fibrinogen counts, although the levels were still within normal limits.

Resumo Introdução e objetivos: O sugamadex é uma substância farmacológica alternativa capaz de reverter o bloqueio neuromuscular sem as limitações apresentadas pelos anticolinesterásicos. Entretanto, há relatos de transtornos de coagulação relacionados ao tratamento com sugamadex sem que mecanismos exatos de seus efeitos sobre a coagulação sejam totalmente compreendidos. O objetivo da presente pesquisa foi avaliar os efeitos do rocurônio, sugamadex e do complexo rocurônio-sugamadex sobre a coagulação em um modelo experimental com ratos. Métodos: Este é um estudo randomizado experimental animal. Ratos Wistar foram aleatoriamente designados aos seguintes grupos: grupo controle; Grupo Ssal - 0,5 mL de solução salina intravenosa; Grupo sugamadex - sugamadex intravenoso (100 mg.kg-1); e Grupo rocurônio-sugamadex - solução intravenosa com rocurônio (3,75 mg.kg-1) e sugamadex (100 mg.kg-1). A anestesia foi realizada utilizando-se isoflurano com ventilação controlada. Os fatores de coagulação foram medidos 10 minutos após o final do preparo pré-operatório e 30 minutos após a administração de drogas de acordo com os grupos escolhidos. Resultados: Contagem de plaquetas, tempo de protrombina e tempo de tromboplastina parcial ativada foram semelhantes entre os grupos e entre os momentos dentro de cada grupo. Houve redução nos níveis de fibrinogênio plasmático entre os tempos 1 e 2 no grupo rocurônio-sugamadex (p = 0,035). Conclusões: O complexo rocurônio-sugamadex promoveu reduções na contagem de fibrinogênio plasmático, apesar de os níveis continuarem dentro dos limites normais.

Pupillary Response to Light is Preserved in Patients without Brain Insult Undergoing Rapid Sequence Intubation

Objective of the Study: This paper has been aimed to determine whether the pharmacological neuromuscular blockade with rocuroniumduring emergency Rapid Sequence Intubation (RSI) affected pupillary response to light (PLR) in patients with brain insult as compared to patients who had non-neurological illness. Previous studies elucidated that RSI with pharmacological neuromuscular blockade does not affect PLR, except in patients with significant neurological lesion. Our objective is to examine the validity of existing but scarce literature on this subject, with further stratification of patients involved in this study into neurological and non-neurological disease groups.Methods:This was a prospective case-reference study of case group with brain insult patients compared with reference group of patients without neurological diseases undergoing RSI in emergency settings. It is single centered study, conducted from October 2019 till May 2020. A pair of a neurosurgeon and a medical officer assessed pupillary light response after administration of neuromuscular blockade and intubation, each blinded to other’s assessment of PLR. Cases without pupillary response before RSI intubation were excluded. The primary outcome measure was clinically observable Pupillary Light Response (PLR) following neuromuscular blockade with Rocuronium in each group.Results:We examined 50 patients undergoing RSIwith Rocuronium, either in emergency department or Intensive Care Unit (ICU), 25 each in index and reference group respectively. All patients in the reference group showed PLR after RSI. Of case group patients receiving RSI, only15 of 25 (60%) demonstrated PLR after RSI. This was statistically significant (p value<0.05) when compared to number of patients with intact PLR after RSI in reference group. Cohen’s Kappa Coefficient (k) for inter-observer agreement was 0.70.Conclusion: Rocuronium does not appearto affect PLR after emergent RSI in patients without brain injury. Only in patients with known brain insult showed impaired PLR, suggesting impaired pupillary light reflex mechanism may be the culprit for this aberration, rather than pharmacological neuromuscular blockade

Influence of methylprednisolone on the reversal time of sugammadex: a randomized clinical trial / Influência da metilprednisolona no tempo de reversão do sugammadex: estudo clínico randomizado

Abstract Background and objectives: Sugammadex is a modified gamma-cyclodextrin that reverses the effects of aminosteroidal neuromuscular blocking agents. Likewise, some steroid molecules, such as toremifene, fusidic acid, and flucloxacillin, can also be encapsulated by sugammadex. Methylprednisolone, which is a synthetic steroid used commonly for airway edema prophylaxis, can also be encapsulated by sugammadex. The objective of this study was to compare the recovery times of sugammadex for reversing rocuronium-induced moderate neuromuscular blockade in those who received intraoperative 1 mg kg-1 methylprednisolone or saline. Method: This single-centered, randomized, controlled, prospective study included 162 adult patients undergoing elective ear-nose-throat procedures (aged from 18 to 65, an ASA physical status I-II, a BMI less than 30 kg m-2, and not taking steroid drug medication) with propofol, remifentanyl, rocuronium and sevoflurane. Neuromuscular monitoring was performed using calibrated acceleromyography. The Control Group (Group C) received 5 mL of saline, while the Methylprednisolone Group (Group M) received 1 mg kg-1 of methylprednisolone in 5 mL of saline just after induction. After the completion of surgery, regarding the TOF count, two reappeared spontaneously and 2 mg kg-1 sugammadex was administered to all patients. Recovery of the TOF ratio to 0.9 was recorded for both groups, and the estimated recovery time to reach a TOF ratio (TOFr) of 0.9 was the primary outcome of the study. Results: Median time to TOFr = 0.9 was for 130.00 s (range of 29-330) for Group C and 181.00 s (100-420) for Group M (p < 0.001). The differences between the two groups were statistically significant. Conclusion: When using 2 mg kg-1 of sugammadex to reverse rocuronium-induced neuromuscular blockade in patients who received 1 mg kg-1 of intraoperative methylprednisolone, demonstrated delayed recovery times.

Resumo Justificativa e objetivos: Sugammadex é uma gama-ciclodextrina modificada que reverte os efeitos de agentes de bloqueio neuromuscular aminoesteroides. Da mesma forma, algumas moléculas esteroides, como toremifene, ácido fusídico e flucloxacilina, podem ser encapsulados pelo sugammadex. A metilprednisolona, esteroide sintético usado geralmente para a profilaxia de edema de vias aéreas, também pode ser encapsulada pelo sugammadex. O objetivo do estudo foi comparar os tempos de recuperação do sugammadex na reversão de bloqueio neuromuscular moderado induzido pelo rocurônio em pacientes em que foi administrado 1 mg.kg-1 de metilprednisolona ou solução salina no período intraoperatório. Método: Este estudo prospectivo, randomizado, controlado, unicêntrico incluiu 162 pacientes adultos (idades de 18-65, ASA I-II, IMC abaixo de 30 kg.m-2, e não usando medicação esteroide) submetidos à anestesia geral para procedimento eletivo de otorrinolaringologia com propofol, remifentanil, rocurônio e sevoflurano. A monitorização neuromuscular foi realizada usando aceleromiógrafo calibrado. O grupo controle (Grupo C) recebeu 5 mL de solução salina, enquanto o grupo metilprednisolona (Grupo M) recebeu 1 mg.kg-1 de metilprednisolona em 5 mL de solução salina logo após a indução. Ao término da cirurgia, em relação à contagem do número de respostas à sequência de quatro estímulos (TOFc), dois pacientes mostraram recuperação espontânea e todos os pacientes receberam 2 mg.kg-1 de sugammadex. A recuperação da razão T4/T1 (TOFr) para 0,9 foi registrada nos dois grupos, e o desfecho primário do estudo foi o tempo estimado de recuperação, momento em que a razão TOFr alcançou o valor de 0,9 (TOFr = 0.9). Resultados: O tempo mediano para TOFr = 0,9 foi 130 s (29-330) para o Grupo C e 181s (100-420) para o Grupo M (p < 0,001). As diferenças entre os dois grupos foi estatisticamente significante. Conclusões: Pacientes que receberam 1 mg.kg-1 de metilprednisolona no intraoperatório apresentaram tempo de recuperação mais prolongado após o uso de 2 mg.kg-1 de sugammadex para reverter o bloqueio neuromuscular induzido pelo rocurônio.

A Study of Hemodynamic Effects of Rocuronium Bromide and other Muscle Relaxants in Cardiac Surgery

Introduction: Use of muscle relaxants in cardiac surgeryposes a challenge to anaesthesia due to narrow margin of safetyand limited cardiovascular function. Therefore aim of presentstudy is to find out the hemodynamic effects of Rocuroniumbromide and other muscle relaxant in cardiac surgery.Material and Methods: Present study was carried out on sixty(60) patients of different age groups from both sexes scheduledfor various cardiac surgical procedures at L.P.S. Institute ofCardiology, GSVM medical college Kanpur during the periodof August 1998 to August 1999. Patients were classified in 3equal groups. Muscle relaxants were given according to thegroup and hemodynamic parameters were recorded carefullyat the interval of two, five and ten minutes.Results: No statistically significant changes were observed insystolic blood pressure, diastolic blood pressure and centralvenous pressure at 2 minutes, 5 minutes and 10 minutes afterthe administration of all three drugs (P >0.05) comparedwith control values. Significant increase in heart rate wasobserved at 2 minutes and 5 minutes after the administrationof Pancuronium (P <0.05).Conclusion: On basis of present study’s result, it can besaid that Rocuronium bromide is safer in cardiac surgery ascompared to Vecuronium & Pancuronium.

Is 1 mg/kg of sugammadex sufficient to reverse moderate neuromuscular block? A randomized clinical trial / ¿Es suficiente 1mg/kg de sugammadex para revertir el bloqueo neuromuscular moderado? Ensayo clínico aleatorizado

Abstract Background: Sugammadex has made it possible to reverse any type of rocuronium-induced block quickly and safely. The most frequent neuromuscular blockade is the moderate one where doses smaller than those recommended by the industry could get a full reversal. Objective: We aimed to evaluate the effectiveness of half the industry recommended dose of sugammadex to reverse a moderate neuromuscular block. Methods: Unicenter phase IV clinical trial that included 34 patients undergoing laparoscopic cholecystectomy. Intravenous general anesthesia was induced, with acceleromyographic monitoring of the neuromuscular block. After the intervention, the block was reversed with all or half the dose of sugammadex recommended for moderate blocks, using a blinded syringe. Results: Patient characteristics of the 2 groups were similar. Mean time to recovery was 3.6± 1.7minutes for the study group and 3.1 ± 1.7minutes for the control group (P=0.42). Reversal of the block was complete with a single dose of sugammadex in all patients. There was an important linear correlation between depth of block and time to recovery. Conclusion: Intraoperative monitoring is essential to allow us to individualize the dose of the neuromuscular blocking agent. To reverse a moderate block under neuromuscular monitoring, a dose of 1 mg/kg is sufficient in most cases and is equally safe and effective.

Resumen Introducción: El sugammadex permite revertir cualquier tipo de bloqueo inducido por rocuronio de forma rápida y segura. El bloqueo neuromuscular más frecuente es el moderado, en el cual dosis inferiores a las recomendadas por la industria podrían revertirlo completamente. Objetivo: Evaluar la efectividad de la mitad de la dosis de sugammadex recomendada por la industria para revertir un bloqueo neuromuscular moderado. Métodos: Ensayo clínico de fase IV en un unico centro que incluyó a 34 pacientes intervenidos de colecistectomía laparoscópica. Se realizó anestesia general intravenosa con monitoreo aceleromiográfico del bloqueo neuromuscular. Tras la intervención, el bloqueo se revirtió con la totalidad o con la mitad de la dosis de sugammadex recomendada para bloqueos moderados, utilizando una jeringa ciega. Resultados: Las características de los pacientes de los dos grupos fueron similares. La media de tiempo de recuperación fue de 3,6 ± 1,7 minutos para el grupo de estudio y de 3,1 ± 1,7 minutos para el grupo de control (p = 0,42). La reversión del bloqueo se completó con una dosis única de sugammadex en todos los pacientes. Hubo una correlación lineal importante entre la profundidad del bloqueo y el tiempo de recuperación. Conclusión: El monitoreo transquirúrgico es esencial para individualizar la dosis del agente de bloqueo neuromuscular. Para revertir un bloqueo moderado bajo monitoreo neuromuscular, una dosis de 1mg/kg es suficiente e igualmente segura y efectiva.

Study on Comparative Effects of Rocuronium and Succinylcholine During Rapid Sequence Intubation

Background: Patients frequently need a rapid sequenceinduction (RSI) endotracheal intubation technique duringemergencies or electively to protect against aspiration inconditions like pregnancy, abdominal pathologies especiallyobstruction or ileus, neurologic disease, or in difficult airway.Traditionally succinylcholine has been the most commonlyused muscle relaxant for this purpose because of its fast onsetand short duration; unfortunately, it can have serious sideeffects. Rocuronium has been suggested as an alternative tosuccinylcholine for intubation.Methods: This study was done at department of anesthesiaSMBT Institute of Medical Science and Research Center,Dhamangaon Tal. Igatpuri, Nashik, Maharashtra, India. Thepatients were systematically randomized into three groups oftwenty each. Group A: Succinylcholine 1.5 mg/kg, Group B:Rocuronium bromide 0.6 mg/kg &Group C: Rocuroniumbromide 0.9 mg/kg.Intubating conditions, onset of action andadverse effects were observed.Results: It was observed that group A & group C patients hadexcellent intubation conditions with faster onset of action forgroup A patients. Adverse effects were not seen in any of thethree groups.Conclusion: Our study concludes that Succinylcholine is anideal agent for intubation in all surgical procedures. Intubatingconditions of Rocuronium bromide at a dose of 0.9mg/kg(3xED95) is comparable to Succinylcholine 1.5mg/kgat1minute. Rocuronium bromide 0.9mg/kg can be used safelyin patients where succinylcholine is contraindicated.

Intubating Laryngeal Mask Airway as an Independent Ventilatory and Intubating Device in Lateral Position: A Fibreoptic Study

Sudden airway loss during surgery in a laterally positionedpatient may have hazardous consequences. We studiedwhether the intubating laryngeal mask airway (ILMA) facilitatesfibreoptic guided tracheal intubation in patients positioned inthe lateral position. Anesthesia was induced with propofol,fentanyl, and rocuronium in 90 consenting patients of eithersex, weighing 50-70 Kg undergoing surgery. Patients wererandomized to three groups (n=30 each); Group 1 (Controlgroup) Supine position, or positioned on their right or left sides(Group 2 and Group 3 respectively) before induction of generalanesthesia. ILMA insertion and fibreoptic guided intubation wasperformed in that position. The grade of the glottic view, timerequired for intubation and number of adjusting maneuversused were recorded. Data were compared by ANOVA, multiple‘t’ test and chi(2) test. Demographic and airway measureswere similar in the three groups. The time required for ILMAinsertion (<30 secs) and success rate was similar in threegroups. The time to intubation was also similar ineach group (15.24±3.4719.68±17.29 secs, 19.35±11.83 secsin Groups 1, 2, 3 respectively; p = > 0.05), as was intubationsuccess (97.7%). Hence ILMA offers a frequent success rateand a clinically acceptable intubation time (<1 min) even in thelateral position.

​Compare Onset Time Of Cisatracurium For Tracheal Intubation With And Without Priming Dose Of Rocuronium

Background: Priming is one of those techniques in which a small dose of non-depolarizing muscle relaxants is administeredfollowed by a large intubating dose. Cisatracurium is the newly introduced drug with Hoffman elimination. The problem with itsuse is delayed onset of action. The present study was conducted to compare the onset of cisatracurium for tracheal intubationwith and without priming dose of rocuronium.Materials and Methods: A total of 60 American Society of Anesthesiologist physical Status Ι and ΙΙ patients undergoing surgeryunder general anesthesia were included in the study. Patients were divided into two groups of 30 each. Patients in Group Rreceived priming dose of rocuronium 0.06 mg/kg before intubating dose of cisatracurium (0.14 mg/kg). Group C patients didnot get any priming, only normal saline was given before intubating dose of cisatracurium (0.15 mg/kg).Results: Time gap between administration of the cisatracurium and complete loss of T1 was recorded as intubation time.The intubation time was significantly less in Group R, i.e., 130 ± 11.02 s as compared to Group C, i.e., 230.33 ± 12.82 s. Theintubating conditions were similar in both the groups. The hemodynamic changes were statistically insignificant. The time to25% recovery of the T1 response is defined as the clinically effective duration of neuromuscular block. The rate of recovery isdescribed by the recovery index, which is defined as the time from 25% to 75% T1 recovery.Conclusion: Priming with rocuronium decreased the onset time without increasing the clinical duration of action or recovery index.

A Comparative Study Of Onset Time And Intubating Condition For Different Dose Of Rocuronium In Burn And Non-Burn Patients

An aberrant pharmacodynamics responses to neuromuscular blocking drugs(NMBD)in burn patients increases the potential for lethal hyperkalemia with the administration of depolarizing muscle relaxant eg:succinylcholine and 2.5–5 folds increase in the dose of plasma concentration requirement for non–depolarizing muscle relaxants like :D–tubocurarine,metacurine,pancuronium,atracurium,vecuronium.Therefore Rocuronium may be the drug of choice in burn patients.This study was planned to assess the onset time and intubating conditions with two different doses of rocuronium in patients with thermal injury.It was concluded that in non–burn patient onset time(loss of response to TOF) was 85.5�4.8 sec with a dose of 0.9 mg/kg as compared to 1.2 mg/kg it was 60.55�70.4,while in burn patients (more than 30% burn area) these values were 120.83�6.81 sec and 86.16�5.2 respectively.

Comparison of sugammadex and pyridostigmine bromide for reversal of rocuronium-induced neuromuscular blockade in short-term pediatric surgery: a prospective randomized study

BACKGROUND: Sugammadex reverses rocuronium-induced neuromuscular blockade quickly and effectively. Herein, we compared the efficacy of sugammadex and pyridostigmine in the reversal of rocuronium-induced light block or minimal block in pediatric patients scheduled for elective entropion surgery. METHODS: A prospective randomized study was conducted in 60 pediatric patients aged 2–11 years who were scheduled for entropion surgery under sevoflurane anesthesia. Neuromuscular blockade was achieved by administration of 0.6 mg/kg rocuronium and assessed using the train-of-four (TOF) technique. Patients were randomly assigned to 2 groups receiving either sugammadex 2 mg/kg or pyridostigmine 0.2 mg/kg and glycopyrrolate 0.01 mg/kg at the end of surgery. Primary outcomes were time from administration of reversal agents to TOF ratio 0.9 and TOF ratio 1.0. Time from the administration of reversal agents to extubation and postoperative adverse events were also recorded. RESULTS: There were no significant differences in the demographic variables. Time from the administration of reversal agents to TOF ratio 0.9 and TOF ratio 1.0 were significantly shorter in the sugammadex group than in the pyridostigmine plus glycopyrrolate group: 1.30 ± 0.84 vs. 3.53 ± 2.73 min (P < 0.001) and 2.75 ± 1.00 vs. 5.73 ± 2.83 min (P < 0.001), respectively. Extubation time was shorter in the sugammadex group. Adverse events, such as skin rash, nausea, vomiting, and postoperative residual neuromuscular blockade (airway obstruction), were not statistically different between the two groups. CONCLUSIONS: Sugammadex provided more rapid reversal of rocuronium-induced neuromuscular blockade in pediatric patients undergoing surgery than did pyridostigmine plus glycopyrrolate.

Anaphylactic shock after sugammadex administration, induced by formation of a sugammadex-rocuronium complex: a case report / 대한마취과학회지

BACKGROUND: Sugammadex is a reversal agent for non-depolarizing neuromuscular blockers and widely used worldwide on account of its rapid and effective reversal from neuromuscular blockade, despite its advantages, multiple cases of sugammadex-induced anaphylactic shock have been reported. CASE: A 42-year-old man developed anaphylactic shock in the postanesthesia care unit. Initially, sugammadex was suspected as the causative agent, but an intradermal skin test revealed negative results. A further skin test was performed with sugammadex-rocuronium complex that yielded positive results. CONCLUSIONS: Anesthesiologists and healthcare providers should be aware of the possibility of anaphylaxis from the sugammadex-rocuronium complex, as well as from sugammadex or rocuronium alone.

Effects of dexamethasone and hydrocortisone on rocuronium-induced neuromuscular blockade and reversal by sugammadex in phrenic nerve-hemidiaphragm rat model / 대한마취과학회지

BACKGROUND: The facilitator effects of steroids on neuromuscular transmission may cause resistance to neuromuscular blocking agents. Additionally, steroids may hinder sugammadex reversal of neuromuscular blockade, but these findings remain controversial. Therefore, we explored the effect of dexamethasone and hydrocortisone on rocuronium-induced neuromuscular blockade and their inhibitory effect on sugammadex. METHODS: We explored the effects of steroids, dexamethasone and hydrocortisone, in vitro using a phrenic nerve-hemidiaphragm rat model. In the first phase, an effective dose of rocuronium was calculated, and in the second phase, following sugammadex administration, the recovery of the train-of-four (TOF) ratio and T1 was evaluated for 30 minutes, and the recovery index was calculated in dexamethasone 0, 0.5, 5, and 50 μg/ml, or hydrocortisone 0, 1, 10, or 100 μg/ml. RESULTS: No significant effect of steroids on the effective dose of rocuronium was observed. The TOF ratios at 30 minutes after sugammadex administration were decreased significantly only at high experimental concentrations of steroids: dexamethasone 50 μg/ml and hydrocortisone 100 μg/ml (P < 0.001 and P = 0.042, respectively). There were no statistical significances in other concentrations. No differences were observed in T1. Recovery index was significantly different only in 100 μg/ml of hydrocortisone (P = 0.03). CONCLUSIONS: Acute exposure to steroids did not resist the neuromuscular blockade caused by rocuronium. And inhibition of sugammadex reversal on rocuronium-induced neuromuscular blockade is unlikely at typical clinical doses of dexamethasone and also hydrocortisone. Conclusively, we can expect proper effects of rocuronium and sugammadex when dexamethasone or hydrocortisone is used during general anesthesia.

Severe Anaphylaxis without Key Signs Such as Urticaria and Bronchospasm Suspected to Be Induced by Rocuronium

Perioperative hypersensitivity reaction have been reported to have a variable degree of the incidence from differ countries and to be 1/353–18,600 approximately and its mortality has been reported to be 4%–4.76% in the United States and Japan, respectively. A 65-year-old male patient with hypertension, rheumatoid arthritis, and history of amoxicillin allergy was scheduled for laparoscopic radical prostatectomy due to prostate cancer. Lidocaine, propofol, and rocuronium were administered sequentially to induce general anesthesia. Twenty minutes after the rocuronium administration, severe hypotension and tachycardia developed. But key signs of hypersensitivity such as urticaria and bronchospasm were not appeared. The operation was canceled and we evaluated the cause of severe hypotension and could confirm hypersensitivity for rocuronium with intradermal test after 4 weeks.

Reversal of neuromuscular block with sugammadex in five heart transplant pediatric recipients / Reversão do bloqueio neuromuscular com sugamadex em cinco receptores pediátricos de transplante cardíaco

Abstract Heart transplantation is a frequent procedure in the treatment of end-stage cardiac dysfunction. Therefore, these patient populations will also be more frequent exposed to other more common surgical procedures after their transplantation. Anesthesiologist should be aware in their assessment of these patients, especially regarding some specific issues related to patients with a history of heart transplantation, like reversal of neuromuscular block. Several reports described that cholinesterase inhibitors drugs, like neostigmine, may produce a dose-dependent life-threatening bradycardia in heart transplant recipients while other publication described the safe use of neostigmine. Reversal of neuromuscular block with sugammadex is another possibility, but limited data exists in literature. We describe five cases in which successful reversal of neuromuscular block was performed with sugammadex in heart transplant pediatric recipients without sequale and discuss the reversal of neuromuscular block in this patient population.

Resumo O transplante cardíaco é um procedimento frequente no tratamento da disfunção cardíaca em estágio final. Portanto, essa população de pacientes também será exposta com mais frequência a outros procedimentos cirúrgicos mais comuns após o transplante. Em sua avaliação, o anestesiologista deve ter em mente algumas questões específicas relacionadas à história de transplante cardíaco desses pacientes, tais como a reversão do bloqueio neuromuscular. Vários estudos relataram que os inibidores da colinesterase, como a neostigmina, podem produzir uma bradicardia dose-dependente que ameaça a vida em receptores de transplante cardíaco, enquanto um estudo relatou o uso seguro de neostigmina. A reversão do bloqueio neuromuscular com sugamadex é outra possibilidade, mas os dados na literatura são escassos. Descrevemos cinco casos nos quais a reversão bem-sucedida do bloqueio neuromuscular foi realizada com sugamadex em receptores pediátricos de transplante cardíaco sem deixar sequelas e discutimos a reversão do bloqueio neuromuscular nessa população de pacientes.

Evaluation Of Intubating Conditions With Rocuronium By Priming Technique. A Randomized Double Blind Study

BACKGROUND: a prospective, randomized, double-blind study was designed to evaluate the effects of priming technique with rocuronium bromide for intubation in adult patients undergoing surgical procedures.METHODS: sixty adult patients of 20-60 years of age with asa-1 physical status posted for surgical procedures were divided in to two groups. group c received normal saline (2ml) as priming dose and group p received 0.06mg/kg rocuronium (2 ml) as priming dose and after 3 minutes intubating dose group c received 6 mg /kg (5 ml) group p received the 5.4 mg /kg (5 ml) as intubating dose .muscle relaxation was assessed with nerve stimulator for every 10 seconds and assessed visually for loss of adduction of thumb and disappearance of t1 of train of four (TOF) stimuli. By this we can note the onset time of intubation (Ti) and intubating conditions were assessed buy cooper et al scoring system. Any adverse effects were also noted.RESULTS: The mean onset of intubation time (Ti) in the group P was 52.33±6.79 sec, in the group C was 95.67±11.04 sec ,P value is 0.00 it is highly significant. Minimum Ti is 80 sec. and maximum Ti is 120 sec. intubation scores as per “cooper et al scoring”were 8 or 9 in both the groups. There were no incidences of weakness, aspiration, bradycardia, ptosis, hypotension, in either of the groups during study observation.CONCLUSION: administration of Priming dose of rocuronium before the intubating dose causes the onset of neuromuscular block is rapid and onset time of intubation is became comparable to that of suxamethonium with excellent intubating conditions and without adverse effects.

A prospective, randomized controlled study to compare the intubating conditions achieved with suxamethonium and rocuronium bromide

Background: Endotracheal intubation is required for giving general anesthesia for which adequate muscle relaxation is necessary Suxamethonium is still used as a relaxant for endotracheal intubation Rocuronium, a nondepolarizing muscle relaxant was compared here for tracheal intubating conditions Aim of the study: To compare the intubating conditions achieved in patients undergoing elective surgeries under General Anaesthesia with Suxamethonium or Rocuronium in 60 secs and complications in both groups Materials and methods: This study was conducted in Institute of Anaesthesiology and Critical care at Madras medical college, Chennai during the period 2014 – 15100 patients of ASA I and II were divided randomly into 2 groups undergoing elective surgeries: Group I - Suxamethonium Group II - Rocuronium assessed for intubating conditions after administration of the corresponding drug Results: The intubating conditions were excellent in group I Suxamethonium as against Group II Rocuronium in 60 secs According to the cooper scoring system the scores of vocal cord movement in group I (Suxamethonium) was 268 (mean) ± 0471 and in group II (Rocuronium) was 234±0557, the scores of response to intubation in group I (Suxamethonium) was 298±0141 and in group II (Rocuronium) was 270±0463 with better intubating conditions in group I receiving Suxamethonium than Rocuronium The results were significant with a p-value of<005 whereas the scores of jaw Stalin R, Raja Manikandan S A prospective, randomized controlled study to compare the intubating conditions achieved with suxamethonium and rocuronium bromide IAIM, 2018; 5(12): 72-76 Page 73 relaxation in group I patients (Suxamethonium) was 270 (mean)±0463 and group II patients (Rocuronium) was 252±0544 with better jaw relaxation Conclusion: Rocuronium can be used as an alternative when suxamethonium is contraindicated for rapid intubation but not if the anticipated difficult airway is present Rocuronium can be chosen as an alternative to it even in rapid sequence intubation in emergency cases, provided the airway is properly assessed and no anticipated difficult intubation is present

Anaphylaxis after rocuronium administration during induction of anesthesia

Anaphylaxis during anesthesia is rare, but often fatal. Rocuronium is a neuromuscular relaxant used for induction of anesthesia. We experienced a case of anaphylaxis after rocuronium administration during induction of anesthesia. A 64-year-old female patient was scheduled for bilateral radius fracture fixation. The history of patient showed no specific findings other than hypersensitivity to mackerel. She had no previous experience of anesthesia. Anesthesia was induced by intravenous injection of propofol 100 mg and continuous infusion was begun with remifentanil 0.25 µg/kg/min, followed by rocuronium 40 mg. Immediately after intravenous administration of rocuronium, the manual ventilation became difficult, and the patient developed erythema and severe hypotension. The patient was diagnosed with anaphylaxis based on clinical features and started treatment. First, we performed endotracheal intubation promptly. Then, immediate intravenous administration of epinephrine and fluid followed. Despite adequate treatment, hypotension was not corrected and intravenous epinephrine was administered. However, ventricular tachycardia occurred which was successfully treated with a defibrillator. Later, the patient uneventfully recovered in the intensive care unit. The patient was not tested for skin prick test, but rocuronium was the most likely cause of anaphylaxis at that time. The authors unexpectedly experienced drug-induced anaphylaxis, which is life-threatening to the patient. Clinicians should be aware of the diagnosis, treatment, and prevention as anaphylaxis can be hazardous to the patient.